Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  Ablynx    ABLX   BE0003877942

ABLYNX (ABLX)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Ablynx
Develops and produces antibodies

Ablynx NV is a is a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand.

It offers programs for inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.

The company was founded on July 4, 2001 and is headquartered in Ghent, Belgium.

Number of employees : 389 persons.
Sales per Businesses
20152016Delta
EUR (in Million)%EUR (in Million)%
Nanobodies76.76100%84.77100% +10.44%
Sales per Regions
20152016Delta
EUR (in Million)%EUR (in Million)%
Belgium76.76100%84.77100% +10.44%
Managers
NameAgeSinceTitle
Edwin Moses, PhD622004Chief Executive Officer & Executive Director
Peter John Fellner, PhD732013Chairman
Wim Ottevaere612006Chief Financial Officer
Antonin Rollet de Fougerolles, PhD522013Chief Scientific Officer
Robert K. Zeldin, MD542015Chief Medical Officer
Remi Vermeiren772007Independent Non-Executive Director
Russell G. Greig, PhD652012Independent Non-Executive Director
Bo Jesper Hansen MD, PhD592013Independent Non-Executive Director
William John Jenkins, MD702013Independent Non-Executive Director
Catherine Moukheibir, MBA572013Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 74,720,644 66,080,697 88.4% 0 0.0% 88.4%
Shareholders
NameEquities%
Van Herk Investments BV 5,883,306 7.87%
FMR LLC 5,813,507 7.78%
Fidelity Management & Research Co. 4,702,970 6.29%
Baker Bros. Advisors LP 4,000,665 5.35%
Farallon Capital Management LLC 3,175,000 4.25%
Consonance Capital Management LP 3,096,059 4.14%
Perceptive Advisors LLC 2,773,439 3.71%
GAM International Management Ltd. 2,408,585 3.22%
C.H. Boehringer Sohn AG & Co. KG 2,142,857 2.87%
OppenheimerFunds, Inc. 1,186,009 1.59%
Markets and indexes
- Euronext Brussels
- Compartiment B
- BEL Mid / Next 150, Next Biotech, PEA, Tech 40
Stock Exchange Codes
- Bloomberg Code :  ABLX:BB
- Reuters Code :  ABLX.BR
- Datastream Code :  
Company contact information
Ablynx
Technologiepark 21
BE-9052 Zwijnaarde, Gent, Oost-Vlaanderen
Belgium

Phone : +32 (0)9 262 00 00
Fax : +32 (0)9 262 00 01
Internet : http://www.ablynx.com
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
ABLYNX87.52%1 805
CELLTRION, INC.--.--%23 756
IQVIA HOLDINGS INC34.41%21 227
INCYTE CORPORATION-2.16%20 346
LONZA GROUP62.09%19 523
ALNYLAM PHARMACEUTICALS, INC.233.49%12 349
NEKTAR THERAPEUTICS361.53%8 960
ALKERMES PLC-7.23%8 092
SEATTLE GENETICS, INC.5.57%7 563
QIAGEN NV10.15%7 414
SAGE THERAPEUTICS INC209.50%6 664
IONIS PHARMACEUTICALS INC12.00%6 520
EXACT SCIENCES CORPORATION288.32%6 173
ICON PLC50.96%6 161
UNITED THERAPEUTICS CORPORATION-4.98%5 938
PRA HEALTH SCIENCES INC61.70%5 719
CHARLES RIVER LABORATORIES INTL. INC39.13%5 119
BIO-TECHNE CORP24.26%4 852
GALAPAGOS17.03%4 649
INC RESEARCH HOLDINGS INC-21.96%4 283
BB BIOTECH AG20.51%3 688
Connections : Ablynx
© 2017 People , Fundamentals and Ownership    © 2017 Cofisem